A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~32 mi. (Castelló de la Plana, Spain, +383 more cities)

Hospital Provincial Castellón

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

~32 mi. (Castelló de la Plana, Spain, +206 more cities)

Hospital Provincial de Castellon; Servicio de Oncologia

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

~32 mi. (Castelló de la Plana, Spain, +115 more cities)

Hospital Provincial de Castellon; Servicio de Oncologia

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

~32 mi. (Castelló de la Plana, Spain, +21 more cities)

Consorcio Hospitalario Provincial de Castellón

ER Positive, +2 more biomarkers

Invasive Breast Carcinoma

abemaciclib, +2 more drugs

hormone therapy, +1 more type

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

~32 mi. (Castelló de la Plana, Spain, +23 more cities)

Hospital Provincial de Castellón

HRAS Mutation

Non-Small Cell Lung Carcinoma, +1 more condition

tipifarnib

targeted therapy

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

~32 mi. (Castelló de la Plana, Spain, +13 more cities)

Hospital Provincial de Castellón

ER Negative, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

~83 mi. (Castelló, Spain, +41 more cities)

Hospital general de Castellón

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

cytarabine, +8 more drugs

chemotherapy, +2 more types

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

~83 mi. (Castelló, Spain, +37 more cities)

Hospital Provincial de Castellón

ER Positive, +2 more biomarkers

Breast Carcinoma

fulvestrant, +2 more drugs

hormone therapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~86 mi. (Valencia, Spain, +89 more cities)

Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1332)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~86 mi. (Valencia, Spain, +226 more cities)

Instituto Valenciano de Oncologia ( Site 0331)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~86 mi. (Valencia, Spain, +140 more cities)

Hospital General Universitario de Valencia ( Site 0595)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~86 mi. (Valencia, Spain, +207 more cities)

Hospital Clinico Universitario de Valencia ( Site 1355)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types